Funding news · Sep 11, 2026
SkinSync AI Raises $300K Seed for AI Medical Aesthetics Platform
SkinSync AI Secures $300K Seed Round
SkinSync AI, a Chicago-based developer of an AI-powered operating platform for medical aesthetics, has raised $300,000 in Seed funding. The round was completed on September 11, 2026, in U.S. dollars.
What the Company Does
SkinSync AI builds software designed to connect medspas, dermatology clinics, and plastic-surgery practices with their patients. The platform pairs real-time facial and skin analysis with treatment visualization, booking, payments, and patient engagement inside a single HIPAA-oriented ecosystem.
The product is delivered through clinic dashboards as well as the SkinSync AI: Botox & Filler apps on iOS and Android, giving providers a mobile-facing layer alongside their back-office tooling.
Company Background
- Founded: 2025
- Founder & CEO: Victoria Almanaseer
- Headquarters: Chicago
- Ownership: Woman-owned
- Technology: Lists patent-pending technology
- Stage: Seed
Round Details
| Item | Detail |
|---|---|
| Round type | Seed |
| Amount | $300,000 |
| Currency | USD |
| Date | September 11, 2026 |
| Lead investor | Not disclosed |
| Participating investors | Not disclosed |
No lead investor or additional participating investors were named in the funding disclosure, and no source URL was provided.
Why It Matters
Medical aesthetics sits at the intersection of clinical workflow software and consumer-facing booking and engagement tools. SkinSync AI's positioning combines both sides: analysis and visualization for the provider, and booking, payments, and engagement for the patient. That combination is intended to keep the patient relationship inside one system rather than spread across separate scheduling, payment, and imaging tools.
The company's HIPAA-oriented framing signals that it is targeting regulated clinical environments — medspas, dermatology practices, and plastic-surgery clinics — where data handling requirements shape software adoption decisions.
Acquisition Angle
For acquirers in healthcare IT, aesthetics practice-management, or consumer health platforms, SkinSync AI represents an early-stage asset with a defined vertical focus. Key attributes to weigh:
- Vertical specificity: The platform is purpose-built for medical aesthetics rather than general practice management, which can shorten product-market fit cycles within the niche.
- Dual-surface product: Clinic dashboards plus consumer mobile apps create two potential integration points — provider workflow and patient acquisition.
- Patent-pending technology: The company states it holds patent-pending technology, which may factor into diligence around defensibility.
- Early stage: At Seed with $300,000 raised, the company is pre-scale, meaning any acquisition interest would likely center on team, technology, and vertical positioning rather than revenue.
What to Watch
With a Seed round of this size, the near-term questions for observers and potential partners will be around clinic adoption, the depth of the AI analysis and visualization capabilities, and how the HIPAA-oriented architecture is validated in practice. The absence of a named lead investor also leaves the cap table and strategic backing undisclosed at this time.
SkinSync AI's combination of a 2025 founding, a woman-owned structure, and a Chicago base places it within a growing cluster of early-stage health-tech ventures targeting specialty clinical workflows.
Funding details as disclosed: $300,000 Seed, USD, dated September 11, 2026. Lead investor and participating investors not disclosed.